GE Healthcare achieved positive results from its multi-center Phase II study of flutemetamol, a positron emission tomography (PET) imaging agent for brain imaging. A Phase III trial program is also currently underway. The study investigated the efficacy of flutemetamol in differentiating between patients with clinically probable Alzheimer’s disease (AD) and cognitively intact healthy volunteers (HVs). Five independent image readers, each blinded to the patient diagnosis, separately deci...